Onyx Biotec

ONYX

Q: Is the debt of Onyx Biotec increasing or decreasing?

Yes, The debt of Onyx Biotec is increasing.Latest debt of Onyx Biotec is ₹28.65 Crs as of Sep-24.This is greater than Mar-24 when it was ₹27.86 Crs.

Q: Is Onyx Biotec stock expensive?

Onyx Biotec is not expensive.Latest PE of Onyx Biotec is 29.25, while 3 year average PE is 38.37. Also latest EV/EBITDA of Onyx Biotec is 0 while 3yr average is 16.35.

Price

Micro Cap

₹91 Cr.

New to Zerodha? Sign-up for free.

Onyx Biotec specializes in manufacturing pharmaceutical products like sterile water ampoule, dry injection, and dry syrup. Their products adhere to global FDA practices, undergo rigorous testing in FDA Certified Laboratories, and maintain international quality standards. The company's core focus is on offering comprehensive product development and manufacturing services to clients.

Onyx Biotec specializes in manufacturing pharmaceutical products like sterile water ampoule, dry in… More

Low

48.90

52W Range

High

97.45

29.91

Sector PE

25.37

P/B

Div.Yield

ROE

12.19%

EBIDTA

ROCE

12.05

EPS

New to Zerodha? Sign-up for free.

Share Price
Financials
Revenue mix
Shareholdings
Peers
Forensics

This data is currently unavailable for this company.

Summary
Profit & Loss
Balance sheet
Cashflow

View Detailed Summary

This data is currently unavailable for this company.

Yearly | Quarterly

(In Cr.)

(In Cr.)
This data is currently unavailable for this company.

Financial Ratio's

(In %)

Detailed P&L Report

(In Cr.)

Detailed Balance Sheet

Financial Year (In Cr.)

Detailed Cash Flow

Product wise
Location wise

ONYX
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

ONYX
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

More Info

Shareholdings

Holders

Detailed Shareholdings

This data is currently unavailable for this company.

Peers

Detailed Peers

Forensics

View Detailed Forensics

Recent events

News
Corporate Actions

Onyx Biotec Says Mankind Pharma Completes Audit Of Dry Powder Injection

Dec 26, 2024

Events:

Quarterly Results

Announcement Date

Jan 10, 2025

More Micro Cap Ideas

See similar 'Micro' cap companies with recent activity

Promoter Buying

Companies where the promoters are bullish

Detailed List

Capex

Companies investing on expansion

Detailed List

Superstar Investor

Companies where well known investors have invested

Detailed List

Popular questions

Business
Financials
Share Price
Shareholdings

What does Onyx Biotec do?

Onyx Biotec is engaged in the business of Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc. Its products are being processed and manufactured in accordance with best Food and Drug Administration (FDA) practices available globally. Its system and product are tested constantly at each level to ensure international standards of quality in-house and FDA Certified Laboratories. Its core business is focused on providing end-to-end product development and manufacturing solutions to its clients.

Who are the competitors of Onyx Biotec?

Onyx Biotec major competitors are Suven Pharma, JB Chem & Pharma, Lasa Supergenerics, Makers Laboratories, Mercury Laboratories, Biofil Chem & Pharma, Rajnish Wellness. Market Cap of Onyx Biotec is ₹89 Crs. While the median market cap of its peers are ₹89 Crs.

Is Onyx Biotec financially stable compared to its competitors?

Onyx Biotec seems to be less financially stable compared to its competitors. Altman Z score of Onyx Biotec is 2.4 and is ranked 5 out of its 8 competitors.

Does Onyx Biotec pay decent dividends?

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Onyx Biotec latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

How has Onyx Biotec allocated its funds?

Companies resources are allocated to majorly unproductive assets like Accounts Receivable

How strong is Onyx Biotec balance sheet?

Balance sheet of Onyx Biotec is moderately strong, But short term working capital might become an issue for this company.

Is the profitablity of Onyx Biotec improving?

Yes, profit is increasing. The profit of Onyx Biotec is ₹4.59 Crs for TTM, ₹3.03 Crs for Mar 2024 and ₹1.84 Crs for Mar 2023.

Is the debt of Onyx Biotec increasing or decreasing?

Yes, The debt of Onyx Biotec is increasing. Latest debt of Onyx Biotec is ₹28.65 Crs as of Sep-24. This is greater than Mar-24 when it was ₹27.86 Crs.

Is Onyx Biotec stock expensive?

Onyx Biotec is not expensive. Latest PE of Onyx Biotec is 29.25, while 3 year average PE is 38.37. Also latest EV/EBITDA of Onyx Biotec is 0 while 3yr average is 16.35.

Has the share price of Onyx Biotec grown faster than its competition?

There is not enough historical data for the companies share price.

Is the promoter bullish about Onyx Biotec?

There is Insufficient data to gauge this.

Are mutual funds buying/selling Onyx Biotec?

There is Insufficient data to gauge this.

ONYX

Share Price

Financials

Revenue mix

Shareholdings

Peers

Forensics

Summary

Profit & Loss

Balance sheet

Cashflow

Product wise

Location wise

Recent events

News

Corporate Actions

Onyx Biotec Says Mankind Pharma Completes Audit Of Dry Powder Injection

Events:

Quarterly Results

More Micro Cap Ideas

Promoter Buying

Capex

Superstar Investor

Popular questions

Business

Financials

Share Price

Shareholdings

What does Onyx Biotec do?

Who are the competitors of Onyx Biotec?

Is Onyx Biotec financially stable compared to its competitors?

Does Onyx Biotec pay decent dividends?

How has Onyx Biotec allocated its funds?

How strong is Onyx Biotec balance sheet?

Is the profitablity of Onyx Biotec improving?

Is the debt of Onyx Biotec increasing or decreasing?

Is Onyx Biotec stock expensive?

Has the share price of Onyx Biotec grown faster than its competition?

Is the promoter bullish about Onyx Biotec?

Are mutual funds buying/selling Onyx Biotec?